Innovative Cellular Therapeutics Holdings Ltd, a director and 10% owner of Lyell Immunopharma, Inc. (), recently sold shares of the company’s common stock. The transaction, reported in a Form 4 filing with the Securities and Exchange Commission, occurred on July 16, 2026.
The reporting person disposed of 10 shares of common stock at a price of $13.73 per share, totaling $137. Following this sale, Innovative Cellular Therapeutics Holdings Ltd beneficially owns 2,857,490 shares of Lyell Immunopharma common stock.The modest sale comes as LYEL shares trade at $12.92, down 46% over the past six months. According to InvestingPro analysis, the stock appears undervalued at current levels, with the company holding a market cap of $316.6 million. InvestingPro offers 11 additional tips and comprehensive financial metrics for investors seeking deeper insights into LYEL’s prospects. The filing was signed by Lei Xiao, Chief Executive Officer of Innovative Cellular Therapeutics Holdings Limited.
In other recent news, Lyell Immunopharma has been the focus of significant developments. The company presented safety and translational data from its Phase 1/2 clinical trial of rondecabtagene autoleucel for large B-cell lymphoma, treating 108 patients with a manufacturing success rate of 97%. Citizens reiterated a Market Outperform rating with a $34 price target, highlighting the company’s clinical progress and financial position. H.C. Wainwright maintained a Buy rating with a $45 price target, noting improvements in the colorectal cancer safety dataset, which addressed previous concerns about side effects. The firm’s colorectal cancer program showed a high overall response rate and median progression-free survival in early dose levels. Citizens also upgraded Lyell’s stock rating based on safety data and a revenue and earnings multiple analysis. The safety update included a new gastrointestinal prophylaxis regimen in an ongoing clinical study. These developments reflect Lyell’s ongoing efforts in advancing its therapeutic programs and addressing safety concerns.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
investment News